Strata Skin Sciences initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen initiated coverage of Strata Skin Sciences with a Buy rating and $5.25 price target. The company is focused on commercializing the Xtrac Excimer Laser for patients with skin disorders including psoriasis, vitiligo, and atopic dermatitis and is available in the U.S. and international markets including South Korea, Japan, China, and Saudi Arabia, Cohen tells investors in a research note. The analyst believes Skin Sciences should be valued in comparison with other innovative technological companies within the medical technology sector. He determined that the company's valuation should be 4.25 times his 2022 revenue estimate of $45.1M, discounted by one year at 10% or $5.25.